In Vitro Diagnostics (IVD) Quality Controls: Global Market

Report Highlights

The global market for in vitro diagnostics quality controls is expected to grow from $1.5 billion in 2024 and is projected to reach $2.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.8% during the forecast period of 2024 to 2029.

Report Inludes

• 40 data tables and 40 additional tables
• An overview of the global market for in vitro diagnostics (IVD) quality controls
• Analysis of global market trends, featuring revenue data for 2021-2023, estimated figures for 2024, and projected CAGRs through 2029
• Evaluation of the current market’s size and revenue growth prospects, along with a market share analysis by test type, manufacturer, product/services, end user and region
• Discussion of market drivers and restraints and other dynamics
• Assessment of the regulatory landscape, including product recalls
• Analysis of the key companies’ market shares, recent M&A activity, acquisitions, joint ventures, partnerships, and patents
• Company profiles,including Abbott, bioMérieux, F. Hoffmann-La Roche Ltd., Siemens Healthineers, and Thermo Fisher Scientific Inc.

Report Scope

This report provides details about the market for in vitro diagnostics quality controls used in checking the in vitro diagnostic devices present in labs, clinics and hospitals. This report will also highlight the current and future market potentiality of in vitro diagnostics quality controls, with a detailed analysis of the competitive environment between companies. Drivers, restraints, opportunities, prevalence or incidence of chronic diseases, and a regulatory scenario assessment will be covered in the current report. The report includes market projections for 2029 and market shares for key players.

Based on test type, the market is segmented into immunodiagnostics, clinical chemistry, hematology and hemostasis, molecular diagnostics, microbiology, and others. Based on products and services, the market is categorized into quality control products, data management solutions and quality assurance services. Based on type of manufacturer, the market is segmented into third-party controls and OEM controls. Based on end users, the market is segmented into hospitals, diagnostic laboratories and academic institutions.

By geographical region, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. Detailed analyses of major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, and GCC countries are covered within the regional segments. For market estimates, data will be provided for 2023 as the base year, with estimates for 2024 and forecast value for 2029.

Analyst Credentials

Partha Sarathi Das– Associate Consultant-Life Science Research
Partha Sarathi has an experience of nearly a decade in multiple domains, including healthcare, life science, biotechnology, pharmaceuticals, and healthcare IT. His expertise is in designing research studies, gathering data, and performing analysis, ultimately providing clients with actionable insights and recommendations based on their unique business needs. Designs proposal and participates in client queries for quick delivery based on their unique business needs. Academically, Parthasarathi holds a master’s degree in Biotechnology and a bachelor’s degree in Industrial Biotechnology.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.